Document Detail

Double-blind, placebo-controlled trial on the effect of piracetam on breath-holding spells.
MedLine Citation:
PMID:  22302459     Owner:  NLM     Status:  Publisher    
Breath-holding spells (BHS) are apparently frightening events occurring in otherwise healthy children. The aim of this study was to evaluate the efficacy of piracetam in the treatment of breath-holding spells. Forty patients with BHS (who were classified into two groups) were involved in a double-blinded placebo-controlled prospective study. Piracetam was given to group A while group B received placebo. Patients were followed monthly for a total period of 4 months. The numbers of attacks/month before and monthly after treatment were documented, and the overall number of attacks/month after treatment was calculated in both groups. The median number of attacks/month before treatment in the two groups was 5.5 and 5, respectively, while after the first month of treatment, it was 2 and 5, respectively. The median overall number of attacks/month after treatment in both groups was 1 and 5, respectively. There was a significant decline of number of attacks after piracetam treatment compared to placebo (p value < 0.001). There were no reported side effects of the piracetam throughout the study period. In conclusion, piracetam is a safe and effective drug for the treatment of breath-holding spells in children.
Happy Sawires; Osama Botrous
Related Documents :
22744629 - Sentinel lymph node biopsy techniques in thyroid pathologies--a meta-analysis.
7822849 - A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.
19724269 - An open-label prospective randomized multicenter study shows very rapid remission of ul...
22702369 - A prospective, randomized comparison of modified pulmonary vein isolation versus conven...
22900909 - Feasibility of 4 patient-reported outcome measures in a registry setting.
18208889 - Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospecti...
14592909 - Myasthenia gravis (mg): epidemiological data and prognostic factors.
18317339 - Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity.
24860179 - Ablation of epicardial ganglionated plexi increases atrial vulnerability to arrhythmias...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-1
Journal Detail:
Title:  European journal of pediatrics     Volume:  -     ISSN:  1432-1076     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603873     Medline TA:  Eur J Pediatr     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Pediatrics, Cairo University, Cairo, Egypt,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  RSV hospitalisation and healthcare utilisation in moderately prematurely born infants.
Next Document:  A 2-month-old infant with vomiting, seizures, and progressive apathy.